Skip to content

Effect of Ayurvedic tratment medicines on Garbhashaya Granti

CLINICAL STUDY ON AYURVEDIC TREATMENT MODALITIES IN THE MANAGEMENT OF VATA-KAPHAJA ARTAVADUSHTI (W.S.R.TO PCOS)

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/12/003183
Enrollment
100
Registered
2012-12-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from Poly Cystic Ovarian Disease

Interventions

Intervention1: Tila Kwatha: Prakshepa : Churna of Trikatu, Bharngi, Guda, Hingutriguna Taila Dose : 20ml of kwatha twice daily, 5ml of taila. Schedule: Kwatha twice daily in Apana kala Duration : 3

Sponsors

IPGT and RA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Rotterdam revised criteria 2004 two out of three criteria if present 1 Hyper androgenism Clinical or Biochemical 2 Oligomenorrhoea Amenorrhoea Anovulation and menstrual irregularities. 3 PCO features on USG more than 10 follicles in a ovary or one cyst of more than 10 mm in size 4 Others 1 Age Adolescent and Reproductive Age group 12 to 40years 2 History of Poly Cystic Ovarian Syndrome in mother or female sibling with clinical manifestations. 5 Ability and willingness to provide signed informed consent.

Exclusion criteria

Exclusion criteria: ï?? Pelvic /Systemic diseases (like Endometriosis, Hydrosalpinx, Fibroid uterus) causing Oligomenorrhoea and Anovulation. ï?? Organic lesions of reproductive tract like T.B, Carcinoma and congenital deformities ï?? Patients suffering from the following clinical conditions will be excluded A) Adrenal Hyperplasia B) Androgen secreting neoplasm C) Thyroid Dysfunction D) Cushingâ??s syndrome E) Cardiac diseases F) Hyperprolactinaemia G) Diabetes Mellitus H) Hypertension I) Chronic Hepatic /Renal Diseases. J) Current or previous (within last 6 months) use of OC Pills, Gluco-cordticoids, Anti-androgens, Ovulation Induction agents, anti diabetic, anti-obesity drugs, or other hormonal drug.

Design outcomes

Primary

MeasureTime frame
1. Attainment of Normal menstrual pattern (21-35 days) 2. Obesity -Waist Hip Ratio, and BMI 3. Regression of Ovarian Cysts- as evidenced by USG and possible Ovulation study. 4. Safety. Timepoint: 3 months

Secondary

MeasureTime frame
1. Changes in Metabolic parameters- FBS: F.Insulin. 2. Changes in Hirsutism(Modified Ferriman-Gallwey (FG) Score) 3. Changes in Acne Score (Pillsbury, et al,1956) 4. Changes in Hormone level- S. FSH, S.LH, and S. Insulin. 5. Improvement in QoL as per PCOSQ. Timepoint: 3 months

Countries

India

Contacts

Public ContactDr L P Dei

IPGT and RA

deilaxmipriya@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026